Mode
Text Size
Log in / Sign up
N/A N=28 Randomized Single-blind Treatment

Investigating the Physiological Effects of Weight Loss on Male Fertility

Male Infertility · Obesity · Weight Loss

Enrolled (actual)
28
Serious AEs
0.0%
Results posted
Nov 2024
Primary outcome: Primary: Sperm Concentration — 53.6; 58.5; 20.1; 15 million sperms/mL

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Low Energy Diet (Dietary_supplement); NHS advice on healthy eating (Other)
Age
Adult · 18+ yrs
Sex
Male
Sponsor
Imperial College London
Primary completion
Aug 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Sperm Concentration
53.6; 58.5; 20.1; 15
SECONDARY
Total Motility
59.5; 60.8; 48.9; 45.4
SECONDARY
Progressive Motility
53.3; 53.9; 42.8; 39.6
SECONDARY
DNA Fragmentation Index (DFI)
7.7; 19.8; 18.4; 11.2
SECONDARY
Testosterone
13.6; 12.4; 15.6; 13.7
SECONDARY
Sex Hormone-Binding Globulin (SHBG)
30.2; 26.4; 24.2; 22.6
SECONDARY
Reactive Oxygen Species (ROS)
13; 5
SECONDARY
Morphology
1.2; 1.9; 0.6; 1.3
SECONDARY
Luteinizing Hormone (LH)
3.3; 2.8; 3.5; 3.7
SECONDARY
Follicle Stimulating Hormone (FSH)
3.8; 4.5; 5.4; 5

Summary

The purpose of this study is to determine the physiological effects of weight loss on seminal parameters in male participants with reduced reproductive capacity. Learning more about the physiological role of weight loss on reproductive function and metabolic profile of overweight and obese men may give us a better understanding of male fertility and improve the management of patients with reduced fertility. The effects of weight loss on seminal quality are not well understood.

Eligibility Criteria

Inclusion Criteria

  • Body mass index (BMI) ≥ 30 kg/m^2 [Part: 1, 2& 3]
  • Evidence of reduced reproductive capacity (e.g. reduced sperm concentration [applicable for study B]

Exclusion Criteria

  • History of undescended testes, testicular surgery or mumps infection
  • Hormonal therapy such as testosterone or selective oestrogen receptor modulators
  • History of systemic cytotoxic therapy or pelvic radiotherapy
  • Chronic systemic disease, such as cardiac, renal or liver failure
  • At least one of the following:

Alcohol intake >30 units per week Smoking daily Recreational drug use at a frequency not less than weekly

  • Acute illness likely to affect the result of study
  • Impaired ability to provide full consent to take part in the study
  • An occupation requiring strenuous physical exercise that may require a high energy diet
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03553927). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search